Syndax Pharmaceuticals (SNDX) Stifel 2026 Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel 2026 Healthcare Conference 2026 summary
12 Nov, 2026Commercial performance and outlook
Revuforj new patient starts rose 20% sequentially; expected continued quarterly growth from KMT2A and NPM1 penetration, with NUP98 also a potential treatment population.
About 50% of patients reach transplant and 50%-60% return to maintenance; KMT2A maintenance returns are trending toward 70%-80%.
Maintenance is expected to contribute more visibly to revenue in 2027, including as NPM1 patients return to therapy.
Niktimvo has about one-third share in 3L+ GVHD; expansion beyond the current ~6,000-patient market toward 15,000-17,000 patients is a growth opportunity.
Niktimvo growth is expected from further share gains and longer treatment duration; margins were 30%-35% this quarter, up from 25%-30% in prior quarters.
Menin program and frontline studies
Management characterized J&J’s bleximenib abstract as early and cautioned that patient populations and efficacy-evaluable definitions complicate comparisons; combinations and tolerability will be important differentiators.
ASH presentations will include frontline Ven/Aza combination data from BEAT AML, with high CR rates and median OS expected to exceed 24 months, plus intensive-chemotherapy data showing high CR, ORR and MRD clearance.
Separate Phase III studies address intensive chemotherapy and Ven/Aza populations; the international study has multiple hundred active enrolling sites and is at least 30% smaller than some competitor trials.
Both Phase III studies have independently powered dual primary endpoints, supporting potential success on either endpoint and an accelerated approval pathway; management cited strong enrollment momentum and a competitive readout timeframe.
MenTain will prospectively randomize patients after transplant to assess maintenance; RAVEN tests Ven/Aza as a bridge to transplant for fit patients with KMT2A AML.
Niktimvo development
A 120-patient, three-arm Phase II study is expected to report in Q1 2027; its six-month response benchmark is about 40%, and it is powered to assess a 20% delta between active arms.
Duration of response and event-free survival, alongside response rate and tolerability, will inform whether axatilimab plus ruxolitinib can reduce steroid exposure and support uptake.
Further frontline development, including a possible axatilimab-ruxolitinib study, will be considered after review of the upcoming datasets and clinician input.
A pivotal frontline study is expected to read out in Q1 2028, comparing Niktimvo strategies with steroids and seeking to reduce steroid use.
Latest events from Syndax Pharmaceuticals
- Earlier-line trials and maintenance dynamics are central to franchise expansion.SNDX
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 82% as Revuforj and Niktimvo grew and clinical programs advanced.SNDX
Q3 2026 - Strong commercial growth and pivotal trial catalysts highlight a transformative year ahead.SNDX
H.C. Wainwright 28th Annual Global Investment Conference - Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis.SNDX
Citigroup’s Biopharma Back to School Summit 2026 - Q2 2026 revenue surged 92% YoY, driven by Revuforj and Niktimvo growth and pipeline progress.SNDX
Q2 2026 - Expanding pipeline and late-stage programs drive growth and value across major indications.SNDX
R&D Day 2026 - Rapid sales growth and pipeline expansion position for multi-billion dollar market leadership.SNDX
H.C. Wainwright 27th Annual Global Investment Conference - Two product launches target multi-billion dollar markets with robust early adoption and expansion plans.SNDX
TD Cowen 45th Annual Healthcare Conference - FDA approves Niktimvo for refractory chronic GVHD, with U.S. launch expected by early Q1 2025.SNDX
FDA Announcement